Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.
Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.
Alvotech Total Payout Yield % Related Terms
Alvotech Total Payout Yield % Historical Data
* Premium members only.
The historical data trend for Alvotech's Total Payout Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:Z45 vs PAHC, COLL, XERS: Total Payout Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alvotech Total Payout Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alvotech's Total Payout Yield % distribution charts can be found below:
* The bar in red indicates where Alvotech's Total Payout Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alvotech (HAM:Z45) has a Total Payout Yield % of 0.00 as of Jul. 15, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Alvotech and its competitors.
Is Alvotech's Total Payout Yield % too high?
Alvotech's current Total Payout Yield % is 0.00. Overall, Alvotech has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Total Payout Yield % compare to PAHC and COLL?
Alvotech's Total Payout Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Drug Manufacturers company?
A good Total Payout Yield % depends on the Drug Manufacturers industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Alvotech and its competitors. Alvotech's current Total Payout Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (HAM:Z45) is currently considered Possible Value Trap. The stock's GF Value™ is €16.65, compared to a current price of €2.95 — trading 82.3% below its estimated fair value. The current Total Payout Yield % is 0.00. Alvotech's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Alvotech (HAM:Z45), the current Total Payout Yield % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alvotech (HAM:Z45) Overvalued in 2026?
Based on GuruFocus' analysis, Alvotech stock appears to be undervalued.
The current stock price of €2.95 is trading 82.3% below its estimated GF Value™ of €16.65.
GuruFocus considers Alvotech to be Possible Value Trap.
Key valuation signals for HAM:Z45:
Total Payout Yield %: 0.00
GF Value™: €16.65 vs. price of €2.95 (82.3% below fair value)
No single metric tells the full story. See the HAM:Z45 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
48GF Score
Get the complete analysis for HAM:Z45
Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Z45 has been successfully added to your 
